<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441285</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS054805</org_study_id>
    <secondary_id>R01NS054805</secondary_id>
    <nct_id>NCT00441285</nct_id>
  </id_info>
  <brief_title>Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)</brief_title>
  <official_title>Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Peruana Cayetano Heredia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if combination drug therapy of praziquantel and
      albendazole is safe and effective to cure neurocysticercosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurocysticercosis is the single major cause of acquired or late-onset epilepsy in the world,
      and a common diagnosis in immigrant populations in the United States and other industrialized
      countries. An estimated 50 million humans are affected by Neurocysticercosis. The disease
      occurs when a parasite called Taenia solium, or the pig tapeworm, infects the brain, forming
      cysts. Neurocysticercosis is generally treated with 1 of 2 drugs, praziquantel or
      albendazole. However, current treatment with either of these drugs alone is not totally
      effective.

      The goal of this trial is to determine if combination drug therapy of praziquantel and
      albendazole is safe and more effective to cure Neurocysticercosis than either drug
      administered alone. This trial will consist of two sub-studies and a parent study.

      In the first substudy which was performed and completed as the initial part and guide to the
      design of the parent study, a series of 32 patients with viable cystic intraparenchymal
      Neurocysticercosis were treated with either albendazole ( 15 mg / kg /d ) + praziquantel ( 50
      mg / kg/ d ) or albendazole+Placebo in a double blind randomized study. Half of patients in
      each group had their seizure disorder treated with phenytoin and the other half with
      carbamazepine (not assigned by the study). The study was designed and powered for
      pharmacokinetic evaluation and exploratory safety so comparative cysticidal efficacy has not
      yet been analyzed. There were no safety concerns. Pharmacokinetics of ABZ and PZQ were
      obtained and described.

      In the parent study, a total of 240 participants ( including the 32 participants from the
      first substudy ) will be randomly chosen to receive albendazole + praziquantel, albendazole +
      placebo or albendazole at an increased dose + placebo for 10 days. These groups will also
      receive other standard medications to manage the disease including appropriate anti-epileptic
      drug therapy. Participants will stay in the hospital for at least 2 weeks after treatment
      begins, which includes 5 days after the end of anti-parasitic treatment. After discharge from
      the hospital, follow-up visits will be on days 21 and 30 after treatment begins, then monthly
      until day 90, and finally every 3 months until completing 18 months. Brain images will be
      taken at 6 and 12 months after treatment begins. For participants, duration of the trial is 1
      year and a half.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1</time_frame>
    <description>- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Substudy - Area Under the Curve of Albendazole in Treatment Days 10 and 11</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11</time_frame>
    <description>- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Substudy - Maximum Concentration of Albendazole</measure>
    <time_frame>Treatment day 1 and Treatment days 10-11</time_frame>
    <description>Highest serum level of Albendazole measured from all level assessments in the curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III Trial - Proportion of Patients Without Remaining Live Cysts</measure>
    <time_frame>Day 180</time_frame>
    <description>Proportion of patients whose 6 month MR does not show viable parasites anymore</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Day 1</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1</time_frame>
    <description>- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Days 10 and 11</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11</time_frame>
    <description>- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Substudy - Safety of Combined Albendazole Plus Praziquantel Therapy</measure>
    <time_frame>90 days post tx</time_frame>
    <description>- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III Trial - Proportion of Cysts Which Resolved</measure>
    <time_frame>Day 180</time_frame>
    <description>Proportion of Viable Brain Parasites which Are not Alive Anymore at 6 Months MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III Trial - Seizure Frequency</measure>
    <time_frame>Day 1 - 540</time_frame>
    <description>Seizure frequency by treatment group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Neurocysticercosis</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>I. ABZ + ABZ Placebo + PZQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II.- ABZ + ABZ Placebo + PZQ Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III .- Albendazole + PZQ Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )
This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel</intervention_name>
    <description>- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.</description>
    <arm_group_label>I. ABZ + ABZ Placebo + PZQ</arm_group_label>
    <other_name>PZQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.
Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.</description>
    <arm_group_label>I. ABZ + ABZ Placebo + PZQ</arm_group_label>
    <arm_group_label>II.- ABZ + ABZ Placebo + PZQ Placebo</arm_group_label>
    <arm_group_label>III .- Albendazole + PZQ Placebo</arm_group_label>
    <other_name>ABZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABZ Placebo</intervention_name>
    <description>- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.</description>
    <arm_group_label>I. ABZ + ABZ Placebo + PZQ</arm_group_label>
    <arm_group_label>II.- ABZ + ABZ Placebo + PZQ Placebo</arm_group_label>
    <other_name>Placebo of Albendazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PZQ Placebo</intervention_name>
    <description>- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.</description>
    <arm_group_label>II.- ABZ + ABZ Placebo + PZQ Placebo</arm_group_label>
    <arm_group_label>III .- Albendazole + PZQ Placebo</arm_group_label>
    <other_name>Placebo of PZQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For parent study:

        Inclusion Criteria:

          -  Male or female individuals between 16 to 65 years of age, with a diagnosis of
             Neurocysticercosis and 20 or less viable cysts.

          -  Patients with a diagnosis of epilepsy secondary to Neurocysticercosis and a history of
             one or more spontaneous seizures within the previous year but not longer than 10
             years.

          -  Willingness to complete a minimum of two weeks of hospitalization.

          -  If female of child bearing potential, negative urine pregnancy testing and willingness
             to use an adequate method of contraception while on study medications and for at least
             3 months following Albendazole therapy.

          -  Normal laboratory values for hematocrit, platelets, white blood cells and glucose and
             normal or decreased values for Alanine transaminase, Aspartate transaminase and
             creatinine.

          -  Negative PPD measurement and if positive ( &gt; 9mm induration in the absence of other
             findings or immunosuppression ) , negative smears for TB.

          -  Negative fecal exam for Taenia eggs or Strongyloides larvae.

        Exclusion Criteria:

          -  Primary generalized seizures ( e.g., not caused by Neurocysticercosis )

          -  A history of generalized epileptic status .

          -  A type of Neurocysticercosis which can expose the patient to increased risk during the
             study.

          -  Patients with persistent or progressive symptomatic intracranial hypertension or
             intracranial hypertension.

          -  Previous therapy with Albendazole or Praziquantel in the previous year.

          -  Pulmonary tuberculosis, or symptoms compatible with tuberculosis not otherwise
             explained.

          -  Active hepatitis

          -  Systemic disease that may affect short term prognosis.

          -  Patients in unstable condition ( consistently abnormal vital signs: body temperature,
             heart rate, respiratory rate, and blood pressure )

          -  Pregnancy during antiparasitic treatment

          -  History of hypersensitivity to Albendazole or Praziquantel

          -  Concurrent treatment with Cimetidine or Theophylline

          -  Chronic alcohol or drug abuse

          -  Unwilling or unable to provide a Computed tomography initially or an Magnetic
             resonance imaging at 6 months ( as patients with ferromagnetic implants ) , Computed
             tomography at the end of therapy.

          -  Unwillingness of subject or legal representative to give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector H. Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. Javier Pretell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Alberto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier A. Bustos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Nacional Edgardo Rebagliati</name>
      <address>
        <city>Lima</city>
        <zip>Lima 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Guillermo Almenara</name>
      <address>
        <city>Lima</city>
        <zip>Lima 5</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Neurologicas</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Peruana Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <results_reference>
    <citation>Garcia HH, Lescano AG, Lanchote VL, Pretell EJ, Gonzales I, Bustos JA, Takayanagui OM, Bonato PS, Horton J, Saavedra H, Gonzalez AE, Gilman RH; Cysticercosis Working Group in Peru. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol. 2011 Jul;72(1):77-84. doi: 10.1111/j.1365-2125.2011.03945.x.</citation>
    <PMID>21332573</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D, Saavedra H, Gavidia M, Rodriguez L, Najar E, Umeres H, Pretell EJ; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug;14(8):687-695. doi: 10.1016/S1473-3099(14)70779-0. Epub 2014 Jul 3.</citation>
    <PMID>24999157</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2007</study_first_posted>
  <results_first_submitted>January 28, 2010</results_first_submitted>
  <results_first_submitted_qc>July 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2013</results_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurocysticercosis</keyword>
  <keyword>NCC</keyword>
  <keyword>praziquantel</keyword>
  <keyword>PZQ</keyword>
  <keyword>albendazole</keyword>
  <keyword>ABZ</keyword>
  <keyword>parasite</keyword>
  <keyword>pig tapeworm</keyword>
  <keyword>Taenia solium</keyword>
  <keyword>epilepsy</keyword>
  <keyword>late-onset epilepsy</keyword>
  <keyword>acquired epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Neurocysticercosis</mesh_term>
    <mesh_term>Cysticercosis</mesh_term>
    <mesh_term>Taeniasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This protocol (2 groups, n=180) was modified by the DSMB to add a pharmacokinetics / safety substudy (two groups, n=32). After the substudy results were available, we were approved to proceed with a modified study design (3 groups, n=240). This second study was terminated after enroling patient 124 because of early efficacy (total n= 132+24, 156)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PK Substudy ABZ+PZQ</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
        </group>
        <group group_id="P2">
          <title>PK Substudy ABZ+Placebo</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
        </group>
        <group group_id="P3">
          <title>Phase III Trial - ABZ+PZQ</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Placebo of ABZ was added to mask the dose of ABZ (see Increased ABZ arm)
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
        </group>
        <group group_id="P4">
          <title>Phase III Trial - Increased ABZ</title>
          <description>Albendazole was given at 22.5 mg / kg / d , divided in two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum of 1200 mg / d, for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening. It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
        </group>
        <group group_id="P5">
          <title>Phase III Trial - Standard ABZ</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Placebo of ABZ was added to mask the dose of ABZ (see Increased ABZ arm)
Placebo of Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The population involves 32 patients in the Phase II substudy and 124 patients in the Phase III main study</population>
      <group_list>
        <group group_id="B1">
          <title>Albendazole + Praziquantel</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
        </group>
        <group group_id="B2">
          <title>Albendazole + Placebo</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
        </group>
        <group group_id="B3">
          <title>Phase III Trial ABZ+PZQ</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
A placebo of ABZ was added to complete to the doses in the Increased ABZ arm
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 10 days.</description>
        </group>
        <group group_id="B4">
          <title>Phase III Trial Increased ABZ</title>
          <description>Albendazole was given at 22.5 mg / kg / d , divided in two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum of 1200 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 10 days.</description>
        </group>
        <group group_id="B5">
          <title>Phase III Trial Standard ABZ</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
A placebo of ABZ was added to complete the doses to the dosage in the Increased ABZ arm
Praziquantel placebo was given in two daily doses, morning and evening,for 10 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="9.7"/>
                    <measurement group_id="B2" value="27.5" spread="11"/>
                    <measurement group_id="B3" value="34" spread="14"/>
                    <measurement group_id="B4" value="34" spread="12"/>
                    <measurement group_id="B5" value="35" spread="13"/>
                    <measurement group_id="B6" value="28" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1</title>
        <description>- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albendazole + Praziquantel</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
          </group>
          <group group_id="O2">
            <title>Albendazole + Placebo</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1</title>
          <description>- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).</description>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1412.2" spread="58124.7" lower_limit="1115.5" upper_limit="1709"/>
                    <measurement group_id="O2" value="1111" spread="32257.1" lower_limit="931.1" upper_limit="1290.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Substudy - Area Under the Curve of Albendazole in Treatment Days 10 and 11</title>
        <description>- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).</description>
        <time_frame>0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albendazole + Praziquantel</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
          </group>
          <group group_id="O2">
            <title>Albendazole + Placebo</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Substudy - Area Under the Curve of Albendazole in Treatment Days 10 and 11</title>
          <description>- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).</description>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4925.3" lower_limit="3548.6" upper_limit="6302"/>
                    <measurement group_id="O2" value="2969.6" lower_limit="2543.8" upper_limit="3395.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Day 1</title>
        <description>- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1</time_frame>
        <population>Carbamazepine and Phenytoin were not assigned by the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Albendazole + Praziquantel</title>
            <description>Albendazole was given at 15 mg/kg/day, divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg/day, for 10 days.
Praziquantel was given at 50 mg/kg/day, divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g/day,for 9 1/2 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Day 1</title>
          <description>- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin</description>
          <population>Carbamazepine and Phenytoin were not assigned by the study.</population>
          <units>ng*h / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbamazepine (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="548.3" spread="320.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phenytoin (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="923.7" spread="424.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Days 10 and 11</title>
        <description>- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin</description>
        <time_frame>0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbamazepine</title>
            <description>Area Under the Curve of Praziquantel in Patients Receiving Carbamazepine</description>
          </group>
          <group group_id="O2">
            <title>Phenytoin</title>
            <description>Area Under the Curve of Praziquantel in Patients Receiving Phenytoin</description>
          </group>
        </group_list>
        <measure>
          <title>PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Days 10 and 11</title>
          <description>- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin</description>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.2" lower_limit="151.7" upper_limit="328.7"/>
                    <measurement group_id="O2" value="550.1" lower_limit="83.3" upper_limit="1183.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Substudy - Maximum Concentration of Albendazole</title>
        <description>Highest serum level of Albendazole measured from all level assessments in the curve.</description>
        <time_frame>Treatment day 1 and Treatment days 10-11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albendazole + Praziquantel</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
          </group>
          <group group_id="O2">
            <title>Albendazole + Placebo</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Substudy - Maximum Concentration of Albendazole</title>
          <description>Highest serum level of Albendazole measured from all level assessments in the curve.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1293.9" spread="3471.6"/>
                    <measurement group_id="O2" value="2232.8" spread="6500.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Substudy - Safety of Combined Albendazole Plus Praziquantel Therapy</title>
        <description>- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy.</description>
        <time_frame>90 days post tx</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albendazole + Praziquantel</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
          </group>
          <group group_id="O2">
            <title>Albendazole + Placebo</title>
            <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Substudy - Safety of Combined Albendazole Plus Praziquantel Therapy</title>
          <description>- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase III Trial - Proportion of Cysts Which Resolved</title>
        <description>Proportion of Viable Brain Parasites which Are not Alive Anymore at 6 Months MRI</description>
        <time_frame>Day 180</time_frame>
        <population>Final population numbers for this analysis not yet defined</population>
        <group_list>
          <group group_id="O1">
            <title>Phase III Trial - ABZ+PZQ</title>
            <description>Main Trial, Arm receiving standard ABZ doses plus active PZQ</description>
          </group>
          <group group_id="O2">
            <title>Phase III Trial - Increased ABZ</title>
            <description>Main Trial, Arm receiving increased ABZ doses, no PZQ</description>
          </group>
          <group group_id="O3">
            <title>Phase III Trial - Standard ABZ</title>
            <description>Main Trial, Arm receiving standard ABZ doses, no PZQ</description>
          </group>
        </group_list>
        <measure>
          <title>Phase III Trial - Proportion of Cysts Which Resolved</title>
          <description>Proportion of Viable Brain Parasites which Are not Alive Anymore at 6 Months MRI</description>
          <population>Final population numbers for this analysis not yet defined</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase III Trial - Proportion of Patients Without Remaining Live Cysts</title>
        <description>Proportion of patients whose 6 month MR does not show viable parasites anymore</description>
        <time_frame>Day 180</time_frame>
        <population>Some patients did not reach the analysis time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase III Trial - ABZ+PZQ</title>
            <description>Main Trial, Arm receiving standard ABZ doses plus active PZQ</description>
          </group>
          <group group_id="O2">
            <title>Phase III Trial - Increased ABZ</title>
            <description>Main Trial, Arm receiving increased ABZ doses, no PZQ</description>
          </group>
          <group group_id="O3">
            <title>Phase III Trial - Standard ABZ</title>
            <description>Main Trial, Arm receiving standard ABZ doses, no PZQ</description>
          </group>
        </group_list>
        <measure>
          <title>Phase III Trial - Proportion of Patients Without Remaining Live Cysts</title>
          <description>Proportion of patients whose 6 month MR does not show viable parasites anymore</description>
          <population>Some patients did not reach the analysis time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase III Trial - Seizure Frequency</title>
        <description>Seizure frequency by treatment group</description>
        <time_frame>Day 1 - 540</time_frame>
        <population>Final population numbers for this analysis not yet defined</population>
        <group_list>
          <group group_id="O1">
            <title>Phase III Trial - ABZ+PZQ</title>
            <description>Main Trial, Arm receiving standard ABZ doses plus active PZQ</description>
          </group>
          <group group_id="O2">
            <title>Phase III Trial - Increased ABZ</title>
            <description>Main Trial, Arm receiving increased ABZ doses, no PZQ</description>
          </group>
          <group group_id="O3">
            <title>Phase III Trial - Standard ABZ</title>
            <description>Main Trial, Arm receiving standard ABZ doses, no PZQ</description>
          </group>
        </group_list>
        <measure>
          <title>Phase III Trial - Seizure Frequency</title>
          <description>Seizure frequency by treatment group</description>
          <population>Final population numbers for this analysis not yet defined</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Number of Serious Adverse Events along the entire follow up (Days 1 - 540)</time_frame>
      <desc>Adverse events by treatment arm in Phase III arms are not yet available because of the blinded nature of the trial</desc>
      <group_list>
        <group group_id="E1">
          <title>Albendazole + Praziquantel</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel was given at 50 mg / kg / d , divided in two daily doses, morning and evening.It is supplied in 600 mg tablets divided in four, so the dose was rounded up to the next 100 mg level, up to a maximum 3.6 g / d , for 9 1/2 days.</description>
        </group>
        <group group_id="E2">
          <title>Albendazole + Placebo</title>
          <description>Albendazole was given at 15 mg / kg / d , divided two daily doses, morning and evening. It is supplied in 200 mg tablets, so the dose was rounded up to the next 100 mg level, up to a maximum 800 mg / d , for 10 days.
Praziquantel placebo was given in two daily doses, morning and evening,for 9 1/2 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged hospitalization</sub_title>
                <description>The Prolonged hospitalization was associated with the disease itself, not because of antiparasitic treatment</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased neutrophilos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Decreased Red blood cells</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Decreased White blood cells</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Decreased indirect bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hector H. Garcia, MD, PhD</name_or_title>
      <organization>Universidad Peruana Cayetano Heredia</organization>
      <phone>+511 3287360</phone>
      <email>hgarcia@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

